What is One BIO?
One BIO operates at the intersection of advanced biotechnology and consumer nutrition, focusing on the restoration of human healthspan through the reintroduction of active plant fibers into the modern diet. By leveraging cutting-edge extraction technology, the company addresses systemic malnutrition and inflammatory disease by targeting the microbiome and immune system. Its market position is defined by a unique ability to transform complex plant-based compounds into highly effective, consumable products. This approach not only disrupts traditional nutritional paradigms but also establishes One BIO as a key player in the burgeoning longevity and precision health markets, where the demand for science-backed, preventative health solutions continues to rise among aging global populations.
How much funding has One BIO raised?
One BIO has raised a total of $27M across 1 funding round:
Series A
$27M
Series A (2024): $27M with participation from iSelect, Better, Skyviews Life Science, ACRE, Alpha Edison, Morado, and Bayer
Key Investors in One BIO
Skyviews Life Science
A specialized advisory firm focusing on the intersection of biotechnology and advanced nutrition to improve individual health outcomes.
Alpha Edison
An investment firm that partners with entrepreneurs leveraging technology to address shifting consumer behaviors and create new market opportunities.
Bayer
A multinational enterprise with deep expertise in pharmaceuticals and nutrition, focused on overcoming challenges related to global population health.
What's next for One BIO?
Looking ahead, One BIO is poised to leverage its recent capital infusion to scale its manufacturing capabilities and broaden its distribution channels. The company's strategic roadmap emphasizes the commercialization of its fiber-based solutions, aiming to integrate its products into everyday consumer goods. By fostering deeper collaborations with industry leaders in life sciences and nutrition, One BIO intends to solidify its intellectual property portfolio and accelerate clinical validation of its health outcomes. The focus remains on eradicating inflammatory conditions through scalable, technology-driven interventions, ensuring that the company remains at the forefront of the global shift toward personalized, preventative health management.
See full One BIO company page
